One notable drawback of engineered T-cell therapies for cancer treatment, like CAR-T and TCR, lies in their ability to only target a single antigen. While these therapies can initially offer a substantial response, they may eventually result in tumor resistance due to antigen escape mechanisms.
In this webinar, Juan F. Vera introduces an innovative method for targeting up to six antigens, offering a more potent and robust anti-tumor response, without requiring genetic modification.
The Multi-Antigen Targeted (MultiTAA) cell therapy method is currently used in clinical trials for treating hematological malignancies, demonstrating high safety and effectiveness. In Juan's presentation, you will gain insights into:
- The improved patient outcomes achieved by targeting multiple antigens through MultiTAA T-cell therapies
- Noteworthy enhancements in the process conducted by Marker Therapeutics, resulting in decreased manufacturing time, reduced contamination risks, and substantial cost savings
- The application of MultiTAA in ongoing clinical trials for treating patients with acute myeloid leukemia (AML) and non-Hodgkin lymphoma (NHL)
Speaker
Juan F. Vera
President & CEO, Marker Therapeutics
Over the past 19 years, Juan F. Vera has worked extensively on the development of innovative T-cell therapies for clinical applications. He possesses extensive proficiency in conducting research in the field of adoptive T-cell therapy.
Before joining Marker Therapeutics, Juan served as an Associate Professor in the Department of Medicine at the Center for Cell and Gene Therapy, Baylor College of Medicine, Houston.
He is a co-investigator on many clinical trials for T-cell therapy in infectious diseases and cancer. Throughout his career, Juan has authored over thirty articles and is a named inventor on thirteen published patents.